RecruitingPhase 3NCT07527078

Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes

A Randomized, Open-label, Parallel-controlled, Multicenter Phase III Clinical Study Comparing the Efficacy and Safety of GZR33 Injection and Insulin Degludec Injection in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antidiabetic Drugs

Sponsor

Gan & Lee Pharmaceuticals.

Enrollment

350 participants

Start Date

Apr 7, 2026

Study Type

INTERVENTIONAL

Conditions

Type 2 Diabetes (T2DM)

Summary

Evaluate the efficacy of GZR33 Injection and Insulin Degludec Injection (Tresiba®) in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antidiabetic Drugs.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called GZR33 Injection and a drug called Insulin Degludec Injection (Tresiba®) for people with type 2 diabetes (t2dm). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGZR33 Injection

GZR33 Injection Administered SC, once-daily

DRUGInsulin Degludec Injection (Tresiba®)

Administered SC, once-daily

Locations(1)

Gan & Lee Pharmaceuticals

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07527078

Related Trials

Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data

NCT07743021

Validation of Hemoglobin A1c in Patients With Inflammatory Arthritis Treated With Sulfasalazine

NCT074166561 location